Iovance Biotherapeutics, Inc. IOVA Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 36.7%+4.1pp | 31.3%-2.9pp | 29.9%+1.2pp | 30.2%+44.9pp | 32.6%+368pp | |
| Operating margin | -127.2%+60.3pp | -153.1%+87.8pp | -166.3%+307pp | -170%+1,231pp | -187.5%+24,362pp | |
| Net margin | -123.9%+52.6pp | -148.4%+78.5pp | -158.8%+292pp | -161.4%+1,182pp | -176.5%+23,439pp | |
| EBITDA margin | -122.6%+59.3pp | -148.3%+85.2pp | -161.4%+299pp | -164.9%+1,200pp | -181.9%+23,752pp | |
| Free cash flow margin | -106.8%+56.6pp | -127.6%+94.3pp | -140.5%+271pp | -134%+1,088pp | -163.4%+21,112pp | |
| Returns | ||||||
| Return on equity | -47.5%+4.3pp | -55.5%+2.0pp | -53.9%+2.8pp | -53.2%+12.2pp | -51.8%+14.9pp | |
| Return on assets | -37.4%+3.5pp | -42.9%+1.1pp | -41.9%+2.5pp | -41.7%+9.5pp | -40.9%+12.2pp | |
| Return on invested capital | -59.5%+2.9pp | -65.2%+4.6pp | -65.2%+12.9pp | -66.6%+27.3pp | -62.4%+49.4pp | |
| Efficiency | ||||||
| Asset turnover | 0.3×+0.1× | 0.3×+0.1× | 0.3×+0.2× | 0.3×+0.2× | 0.2×+0.2× | |
| Inventory turnover | 2.9×-0.5× | 3.5×0.0× | 3.9×— | 4.3×— | 3.4×— | |
| Liquidity | ||||||
| Current ratio | 3.6×-0.6× | 3.2×-0.5× | 3.4×-0.8× | 3.3×-1.9× | 4.2×-0.5× | |
| Quick ratio | 3.2×-0.5× | 2.8×-0.5× | 3×-0.9× | 2.9×-2.0× | 3.6×-0.8× | |
| Cash ratio | 1.5×+0.1× | 1.2×+0.2× | 1.3×-0.2× | 1×-1.5× | 1.4×-0.2× | |
| Leverage | ||||||
| Debt-to-equity | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | 0.1×-0.1× | |
| Debt-to-assets | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | |
| Per Share | ||||||
| Book value per share | $1.72-27.5% | $1.95-20.2% | —— | $2.09-22.6% | $2.38-6.9% | |
| Valuation | ||||||
| Market capitalization | $1.45B+32.4% | $1.08B-51.9% | $785.22M-70.6% | $627.8M-70.6% | $1.09B-71.2% | |
| Enterprise value | $1.3B+33.2% | $969.09M-55.9% | $678.58M-73.7% | $547.49M-72.4% | $972.88M-74.0% | |
| Price / sales | 5.1×-0.1× | 4.1×-9.6× | 3.1×-26.3× | 2.6×-62.6× | 5.1×-1,987× | |
| Price / book | 2×+0.6× | 1.6×-1.6× | 1.1×-2.3× | 0.9×-1.9× | 1.4×-4.2× | |
| EV / sales | 4.5×0.0× | 3.7×-9.7× | 2.7×-25.7× | 2.3×-58.2× | 4.6×-1,961× | |
| Free cash flow yield | -21.1%+10.7pp | -31%-14.9pp | -44.8%-30.8pp | -51.5%-32.8pp | -31.8%-21.1pp | |
| Earnings yield | -24.5%+9.9pp | -36.1%-19.6pp | -50.6%-35.3pp | -62.1%-41.5pp | -34.4%-22.5pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Iovance Biotherapeutics, Inc.'s profit margins?
- Iovance Biotherapeutics, Inc. (IOVA) runs a 36.7% gross margin and a -127.2% operating margin, with a -123.9% net margin.
- Where do Iovance Biotherapeutics, Inc.'s ratios come from?
- Every ratio is computed from Iovance Biotherapeutics, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
